Brief: Turnstone Biologics Presents Preclinical Data Highlighting Potential For Tumor-Infiltrating Lymphocyte Therapy
03/11/2023 10:12
Nov 3 (Reuters) - Turnstone Biologics Corp TSBX.O :
* TURNSTONE BIOLOGICS PRESENTS PRECLINICAL DATA HIGHLIGHTING
POTENTIAL FOR SELECTED TUMOR-INFILTRATING LYMPHOCYTE (TIL)
THERAPY IN SOLID TUMORS AT THE 2023 SOCIETY FOR IMMUNOTHERAPY OF
CANCER (SITC) ANNUAL MEETING
Source text for Eikon: ID:nGNX35LLzL
Further company coverage: TSBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Turnstone Biologics
See all newsBrief: Turnstone Biologics to Be Acquired by XOMA for $0.34/Share Plus Contingent Value Right
U.S. STOCKS ON THE MOVE-Walmart, crypto, banks
Turnstone rises as company cuts job, changes executives
Brief: Turnstone Biologics Sees One-Time Severance-Related Charge Associated With Workforce Reduction To Be About $2.3 Million
Brief: Turnstone Biologics Announces Strategic Restructuring To Prioritize Portfolio And Extend Financial Runway